Hepatitis D Virus (HDV) Antibody, IgG and IgM

TEST: 144012
Test number copied
CPT: 86692
Updated on 12/4/2024
Print Share

Synonyms

  • HBV
  • Hepatitis delta

Special Instructions

This assay currently is not available in New York state.

This test is not approved in New York state.

This assay currently is not available in New York state.

Expected Turnaround Time

Daily

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Documents

Specimen Requirements

Specimen

Serum or EDTA-plasma

Volume

0.5 mL

Minimum Volume

0.2 mL (Note: This volume does not allow for repeat testing.)

Container

Gel-barrier tube or lavender-top (EDTA) tube

Collection

Standard blood collection technique

Storage Instructions

Room temperature

Stability Requirements

TemperaturePeriod
Room temperature14 days
Refrigerated14 days
Frozen14 days
Freeze/thaw cyclesStable x3

Causes for Rejection

Gross hemolysis, lipemia or visible microbial contamination; heat-inactivated samples; specimens other than serum and EDTA plasma

Test Details

Use

This assay is used for the qualitative detection of Hepatitis D virus (HDV) antibodies (IgG/IgM) and is intended to aid in the diagnosis of HDV infection in individuals with known HBV infection (HBsAg-positive). Testing for HDV RNA should be performed on HDV antibody-positive individuals to differentiate between active and resolved HDV infection.

Limitations

A reactive specimen should be investigated further with sensitive, supplemental HDV-specific tests, such as identification of HDV RNA, to be matched with the clinical story of the subject and with markers of a previous HBV infection (HBsAg, anti-HB Core, HBV DNA, etc.). Like all immunoassays, this assay may occasionally yield nonspecific reactions due to other causes. A nonreactive test result for HDV antibodies does not exclude the possibility of exposure to or infection with HDV. Further investigations with alternative HDV-specific tests are suggested in case of suspected infection despite the negative finding.

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

Methodology

Chemiluminescent immunoassay (CLIA)

References

European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis delta virus. J Hepatol. 2023 Aug;79(2):433-460. Epub 2023 Jun 24.37364791
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr; 67(4):1560-1599.2940532

LOINC® Map

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf